Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion

Am J Surg. 1994 Jul;168(1):36-40. doi: 10.1016/s0002-9610(05)80068-6.


The effects of postoperative immunochemotherapy including the streptococcal preparation OK-432 on the rate of peritoneal recurrence and survival time after curative resection were studied in 36 patients with gastric cancer. Patients randomized to group B received 18 months of a therapy that is widely used in Japan for patients with gastric cancer: mitomycin C (MMC) and UFT, a combination of tegafur and uracil in a molar ratio of 1:4. Patients randomized to group A received the same drugs given to group B plus an intraperitoneal injection of OK-432 on postoperative day 0 and intradermal injections of OK-432 for 18 months at 2-week intervals. There were no differences between the two groups in any known prognostic factor or dose of any drug received, except for OK-432. There was no difference in the toxicity rates between the groups. The concomitant administration OK-432 and anticancer drugs significantly decreased the rates of peritoneal recurrence and lengthened survival time (P < 0.05).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Female
  • Gastrectomy
  • Humans
  • Injections, Intradermal
  • Injections, Intraperitoneal
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Neoplasm Recurrence, Local / epidemiology*
  • Neoplasm Recurrence, Local / secondary*
  • Neoplasm Staging
  • Peritoneal Neoplasms / epidemiology*
  • Peritoneal Neoplasms / secondary*
  • Picibanil / therapeutic use*
  • Postoperative Care / methods*
  • Prognosis
  • Prospective Studies
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy*
  • Survival Rate
  • Tegafur / administration & dosage
  • Treatment Outcome
  • Uracil / administration & dosage


  • Adjuvants, Immunologic
  • Tegafur
  • Picibanil
  • Mitomycin
  • Uracil